Faron Pharmaceuticals Oy
LSE:FARN
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
150
262.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| FI |
|
Faron Pharmaceuticals Oy
LSE:FARN
|
180.5m GBP |
Loading...
|
|
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD |
Loading...
|
|
| US |
|
Abbvie Inc
NYSE:ABBV
|
380.6B USD |
Loading...
|
|
| US |
|
Amgen Inc
NASDAQ:AMGN
|
181.5B USD |
Loading...
|
|
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
157.6B USD |
Loading...
|
|
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
116.2B USD |
Loading...
|
|
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR |
Loading...
|
|
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD |
Loading...
|
|
| AU |
|
CSL Ltd
ASX:CSL
|
85.3B AUD |
Loading...
|
|
| NL |
|
argenx SE
XBRU:ARGX
|
42.5B EUR |
Loading...
|
|
| US |
|
Alnylam Pharmaceuticals Inc
NASDAQ:ALNY
|
46.7B USD |
Loading...
|
Market Distribution
Other Profitability Ratios
Faron Pharmaceuticals Oy
Glance View
Faron Pharmaceuticals Oy is a clinical stage biopharmaceutical company, which engages in the development of treatment for acute organ traumas, vascular damage, and cancer immunotherapy. The company is headquartered in Turku, Lansi-Suomen and currently employs 37 full-time employees. The company went IPO on 2015-11-17. The Company’s pipeline is based on endothelial receptors involved in regulation of immune responses and focuses on acute organ traumas, vascular damage and cancer immunotherapy. The firm has two technological platforms: Traumakine and Clevegen. Traumakine aims to prevent vascular leakage and organ failure under ischemic condition. The company is undergoing Phase III clinical trials for the treatment of Acute Respiratory Distress Syndrome (ARDS) and European Phase II trial for the prevention of multi-organ failure after emergency aortic surgery for a Rupture of Abdominal Aorta Aneurysm (RAAA). Clevegen is a ground breaking early clinical anti-Clever-1 antibody able to switch immune suppression to immune activation in various conditions, with potential across oncology, infectious disease and vaccine development. The company may be used alone or in combination with other immune checkpoint molecules.